

## Evonik appoints Dr. Dirk Hoehler as head of the amino acids business of Animal Nutrition

4 October 2023

- Hoehler has wealth of experience within the Evonik Group
- Track record in Marketing & Sales including digitalization of business processes
- Focus on sustainability, efficiency, and cost-leadership of amino acids business of Evonik

**Main press contact**

**Yama Olumi**

Head of Market Communications  
Animal Nutrition  
Phone + 49 6181 59-12437  
yama.olumi@evonik.com

**Alternative press contact**

**Dr. Jürgen Krauter**

Head of Market Communications  
Evonik  
Phone +49 6181 59-6847  
juergen.krauter@evonik.com

**Essen, Germany.** Evonik has appointed Dr. Dirk Hoehler as the new head of the Essential Nutrition product line, under which Evonik is consolidating its amino acids portfolio. Hoehler will take over the role from Dr. Jan-Olaf Barth, who has been promoted to become the head of the High Performance Polymers business line of Evonik.

Hoehler will be responsible for overseeing the continued transformation of the amino acids business by focusing on sustainability, efficiency, and cost-leadership. In particular, he will continue to implement the global methionine asset strategy developed under Jan-Olaf Barth's direction to secure Evonik's leading position in methionine.

Earlier this year, Evonik announced that it will streamline the operating model for its amino acids business, characterized by a lean sales organization with strong digital capabilities and processes. A key element is also the continuous investments in its methionine world-scale production hubs, which will lead to efficiency improvements and reductions in carbon footprint of six percent (Singapore) and seven percent (Mobile).

As one of Hoehler's priorities, he will ensure the smooth implementation of the planned shutdowns of the methionine Singapore plant on Jurong Island, starting this quarter.

Hoehler says, "We fully understand that these shutdowns may pose challenges for our customers and our teams have prepared mitigation plans for MetAMINO® supply from our global production network. We are in continuous communication with regional and global customers to carefully plan shipments."

**Evonik Industries AG**

Rellinghauser Straße 1-11  
45128 Essen  
Germany  
Phone +49 201 177-01  
www.evonik.com

Supervisory Board  
Bernd Tönjes, Chairman  
Executive Board  
Christian Kullmann, Chairman  
Dr. Harald Schwager, Deputy Chairman  
Thomas Wessel, Maïke Schuh

Registered Office is Essen  
Register Court Essen Local Court  
Commercial Registry B 19474

Dirk Hoehler brings to the role a wealth of experience in several parts of the Evonik Group, having been head of Marketing & Sales of Performance Intermediates and recently head of Sales at Animal Nutrition.

Dirk Hoehler joined the group in 1998 as Manager of Animal Nutrition and served between 2000–2008 as Director Nutrition & Technical Services in Kennesaw (USA). He was subsequently head of the Coating Resins product line and head of Marketing & Sales of the Performance Intermediates business line at Evonik Performance Materials before taking up his current role.

He holds a Ph.D. and Habilitation in Nutritional Physiology, studying at the Universities of Giessen and Kiel, Germany, and the University of Manitoba in Canada.

The Essential Nutrition product line is part of Evonik's Animal Nutrition business and includes products such as MetAMINO® (DL-methionine), Biolys® (source for lysine), and ThreAMINO® (threonine).

#### **Company information**

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.

#### **About Nutrition & Care**

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.

#### **Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.